Released May 16, 2022, after the close
10-Q filed May 16, 2022, 46 days after period end · 0001193125-22-151851
Q1 2022 · 10-Q
Revenue—
Net Income-$9.13M-$9.13M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.23-$0.23 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$9,206,000N/M
Operating Cash Flow-$8,299,000N/M
Free Cash Flowderived-$8,308,000—
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Net Income | -$9.13M | -$27.00M |
| EPS Diluted | -$0.23 | -$64.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR